Digestive System Disease Clinical Trial
Official title:
A Clinical Study to Assess the Effect of a Supplement on Digestive Health, Overall Well-being, and Participant Experience.
Verified date | March 2024 |
Source | Amway Corp |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study aims to evaluate the effectiveness of a dietary supplement (greens powder), on improving digestive health, quality of life, energy levels, and satiety over a 14-day period. Participants, aged 18-65 and experiencing mild digestive issues, will consume the greens powder daily and report outcomes through diaries and questionnaires.
Status | Completed |
Enrollment | 70 |
Est. completion date | February 15, 2024 |
Est. primary completion date | February 15, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Male or female. - Aged 18-65 years. - Willing to comply with study requirements. - No known allergies to the ingredients listed in the product. - Self-reported mild digestive issues (e.g., occasional bloating, stomach discomfort, occasional constipation, or occasional diarrhea). - Generally healthy - do not live with any uncontrolled chronic disease . Exclusion Criteria: - Pre-existing chronic conditions that would prevent adherence to the protocol, including oncological and psychiatric disorders. - Known severe allergic reactions that require an Epi-Pen. - Women who are pregnant, breastfeeding, or attempting to conceive. - History of severe diagnosed digestive disorders (e.g., IBS, IBD, Crohn's disease) or gastrointestinal-tract surgeries. - Unwillingness to follow the study protocol. - Invasive medical procedure within the last three weeks or planning one during the study period. - History of substance abuse. - Current participation or planning to participate in another research study. - Regular consumption of probiotics, fiber, or prebiotic supplements within 3 weeks of the study. - Regular intake of medications that may interfere with the study or study product (e.g., anticoagulants, laxatives, sedatives, beta-blockers, anti-acids) . |
Country | Name | City | State |
---|---|---|---|
United States | Citruslabs | Santa Monica | California |
Lead Sponsor | Collaborator |
---|---|
Amway Corp | Citruslabs |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Digestive Health Improvement | Measure the change in digestive health using daily diaries and the Bristol Stool Scale (BSS). | 14 days from the start of intervention | |
Secondary | Quality of Life and Well-being Enhancement | Assess improvements in participants' quality of life, energy levels, satiety, and overall well-being through validated questionnaires. | 14 days from the start of intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05066139 -
Multidisciplinary Evaluation of Elderly Patients With Digestive Cancer (EPODIG-G)
|
N/A | |
Recruiting |
NCT04475952 -
Early Diagnosis of Upper Digestive Tract Disease
|
||
Completed |
NCT05064163 -
SROI Project on the Surgical Waiting List Management System
|
||
Completed |
NCT03549494 -
Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction
|
Phase 2 | |
Completed |
NCT03559543 -
Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma
|
Phase 2 | |
Completed |
NCT03723447 -
Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)
|
Phase 4 | |
Enrolling by invitation |
NCT01483248 -
Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis
|
Phase 1/Phase 2 | |
Completed |
NCT03008460 -
Efficacy, Safety and Tolerability of Eziclen®/Izinova® Versus Klean-prep® on Bowel Cleansing in Adolescents Undergoing Colonoscopy
|
Phase 3 | |
Active, not recruiting |
NCT05253859 -
CFTR Modulators and Gastrointestinal Complications
|
||
Not yet recruiting |
NCT05636657 -
Comparative Study of Intestinal Color Ultrasound and Capsule Endoscopy in Monitoring Crohn's Disease
|
||
Completed |
NCT05160077 -
Optoacoustic Characterization of Postprandial Intestinal Blood Flow
|
N/A | |
Recruiting |
NCT05401058 -
Low-dose Droperidol for Prevention of Postoperative Delirium in Elderly Patients After Non-cardiac Surgery
|
N/A | |
Not yet recruiting |
NCT06271538 -
Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome
|
Phase 4 | |
Terminated |
NCT03594331 -
Gastric Gluten-Degradation Activity of PvP001
|
Phase 1 | |
Not yet recruiting |
NCT05405842 -
Transauricular Vagal Nerve Stimulation; Functional Dyspepsia and Gastroparesis
|
N/A | |
Recruiting |
NCT06351202 -
Impact Assessment of Abdominal Massage on Feeding Tolerance of Preterms
|
N/A | |
Completed |
NCT02785783 -
Endorings™ Assisted Colonoscopy Versus Standard Colonoscopy for Polyp Detection
|
N/A | |
Completed |
NCT00072943 -
A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease
|
Phase 2 | |
Completed |
NCT03037385 -
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT05827679 -
Creation and Validation of a Clinical Evaluation Scale for Abdominal Condition of the Premature (ECAP)
|